Table 4.
Source of variation | Total variation (%) | P-value | P-value summary | Significant? |
---|---|---|---|---|
GNP-lestaurtinib, days 1–14 | ||||
OCI-AML3 | ||||
Interaction | 18.46 | <0.0001 | **** | Yes |
Time | 66.70 | <0.0001 | **** | Yes |
Column factor | 13.85 | <0.0001 | **** | Yes |
THP1 | ||||
Interaction | 21.97 | <0.0001 | **** | Yes |
Time | 56.50 | <0.0001 | **** | Yes |
Column factor | 21.10 | <0.0001 | **** | Yes |
GNP-quizartinib, days 1–14 | ||||
OCI-AML3 | ||||
Interaction | 19.24 | <0.0001 | **** | Yes |
Time | 54.23 | <0.0001 | **** | Yes |
Column factor | 25.85 | <0.0001 | **** | Yes |
THP1 | ||||
Interaction | 21.91 | <0.0001 | **** | Yes |
Time | 56.90 | <0.0001 | **** | Yes |
Column factor | 20.62 | <0.0001 | **** | Yes |
GNP-sorafenib, days 1–14 | ||||
OCI-AML3 | ||||
Interaction | 7.652 | <0.0001 | **** | Yes |
Time | 83.37 | <0.0001 | **** | Yes |
Column factor | 8.213 | <0.0001 | **** | Yes |
THP1 | ||||
Interaction | 8.526 | <0.0001 | **** | Yes |
Time | 80.74 | <0.0001 | **** | Yes |
Column factor | 10.02 | <0.0001 | **** | Yes |
Note:
Statistically significant.
Abbreviations: GNP, gold nanoparticle; TKI, tyrosine kinase inhibitor.